PI

Protease inhibitors

Protease inhibitors (PIs) are antiviral drugs that target and block viral protease enzymes, which are essential for processing viral polyproteins into functional units. By inhibiting this process, PIs prevent the maturation and replication of viral particles, making them effective in treating various viral diseases.

1. HIV (Human Immunodeficiency Virus)

Mechanism: HIV protease cleaves large polyproteins into smaller functional proteins necessary for viral assembly. PIs block this cleavage, leading to the production of immature, non-infectious viral particles.

• Lopinavir/ritonavir: Ritonavir boosts lopinavir levels, increasing its effectiveness.
• Atazanavir: Known for once-daily dosing and lower lipid disturbances.
• Darunavir: Effective in patients with drug-resistant HIV strains.

2. Hepatitis C Virus (HCV)

Mechanism: HCV protease (NS3/4A protease) processes viral polyproteins required for viral replication. Inhibiting this enzyme blocks the production of functional viral components.

• Simeprevir: Used in combination therapy to treat chronic HCV infection.
• Glecaprevir: Part of a combination regimen for treating various genotypes of HCV.
• Voxilaprevir: Often used in combination with other antivirals to target resistant HCV strains.

3. SARS-CoV-2 (COVID-19)

Protease inhibitors target the Mpro (3CL protease), a key enzyme involved in the cleavage of viral polyproteins required for SARS-CoV-2 replication.

• Nirmatrelvir/ritonavir (Paxlovid): Nirmatrelvir inhibits the SARS-CoV-2 protease, while ritonavir boosts its efficacy by inhibiting metabolism, used to reduce the severity of COVID-19 in high-risk patients.

In each case, protease inhibitors work by interrupting viral replication, making them a crucial part of antiviral therapy across multiple viral diseases.